Cargando…

OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab

Disclosure: I. Shamsudeen: None. B.W. McCrindle: Consulting Fee; Self; Jansen Pharmaceuticals, Amryt, Ultragenyx, Chiesi, Esperion. R.A. Hegele: Advisory Board Member; Self; Amgen Inc, HLS Pharmaceuticals, Novartis Pharmaceuticals. Consulting Fee; Self; Akcea Therapeutics, Ultragenyx, Medison, Acast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shamsudeen, Isabel, McCrindle, Brian W, Hegele, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Cardiovascular Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554401/ http://dx.doi.org/10.1210/jendso/bvad114.673

Ejemplares similares

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

SUN-070 Asymptomatic Patients with Homozygous Familial Hypercholesterolemia: A Challenge
por: Lam, Cesar, et al.
Publicado: (2019)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
por: Stefanutti, Claudia, et al.
Publicado: (2022)

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
por: Rosenson, Robert S., et al.
Publicado: (2023)

Multiple Xanthoma Tuberosum in a Case of Familial Homozygous Hypercholesterolemia
por: Singhania, Pankaj, et al.
Publicado: (2022)

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
por: Banerjee, Poulabi, et al.
Publicado: (2019)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Homozygous Familial Hypercholesterolemia: Case Series and Review of the Literature
por: Palacio, Carlos H., et al.
Publicado: (2011)

SAT-566 Avoiding the Heartache: A Case of Familial Hypercholesterolemia
por: Kinaan, Mustafa, et al.
Publicado: (2020)

ODP137 Achilles Tendon Size and Characteristics for Diagnosis of Familial Hypercholesterolemia Among Thai Patients
por: Warachit Parksook, Wasita, et al.
Publicado: (2022)

Xanthoma tuberosum in homozygous familial hypercholesterolemia
por: Moorthy, Nagaraja, et al.
Publicado: (2014)

Liver Transplantation for Homozygous Familial Hypercholesterolemia
por: Ishigaki, Yasushi, et al.
Publicado: (2019)

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
por: Bajaj, Archna, et al.
Publicado: (2022)

Severe Hypercholesterolemia in Very-Low-Carbohydrate Diet
por: Modarressi, Taher
Publicado: (2021)

SUN-561 Genetic Variants Related to Familial Hypercholesterolemia in Clusters from Minas Gerais - a Southeast State of Brazil
por: de Paiva Silvino, Júnea Paolucci, et al.
Publicado: (2020)

SAT-087 Familial Generalized Lipodystrophy in Two Siblings Due to Homozygous p.Arg545His LMNA Mutation
por: Patni, Nivedita, et al.
Publicado: (2019)

Diet-Responsive Hypercholesterolemia With Cardiofaciocutaneous Syndrome Type 3
por: Patni, Nivedita, et al.
Publicado: (2021)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2015)

Homozygous familial hypercholesterolemia with an update on cholesterol management
por: Velvet, Anju J J, et al.
Publicado: (2020)

New algorithms for treating homozygous familial hypercholesterolemia
por: Tromp, Tycho R., et al.
Publicado: (2022)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2022)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

SAT-565 Familial Homozygous Lipoprotein Lipase Defect Presenting with Recurrent Chylomicronemia Syndrome: Making a Case for Elective Plasmapheresis as an Adjuvant Treatment Modality
por: Shaka, Hafeez, et al.
Publicado: (2020)

Homozygous Familial Hypercholesterolemia Associated with Symmetric Subcutaneous Lipomatosis
por: Dawoud, Noha Mohammed, et al.
Publicado: (2015)

Premature Valvular Heart Disease in Homozygous Familial Hypercholesterolemia
por: Fahed, Akl C., et al.
Publicado: (2017)

Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form − 5 Years Follow-Up
por: Vladimirova-Kitova, Lyudmila, et al.
Publicado: (2021)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes
por: Derenbecker, Robert, et al.
Publicado: (2019)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

ANGPTL8: An Important Regulator in Metabolic Disorders
por: Luo, Mengdie, et al.
Publicado: (2018)

Applications of machine learning in familial hypercholesterolemia
por: Luo, Ren-Fei, et al.
Publicado: (2023)

Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
por: Walzer, S, et al.
Publicado: (2013)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

Evidence-Based, Mechanistic Approach to the Management of Homozygous Familial Hypercholesterolemia
por: Rosenson, Robert S.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ennvtua82f79fr9qvu2m6lo9v